nuvalent is improving human health by developing breakthrough small molecule therapeutics that engage biological targets in new ways using cutting-edge chemical insights. by expanding the universe of targets that interact with small molecules, we are generating therapeutics with activities not previously possible, including modulation of ‘undruggable’ targets. our unique approach is leading to first-in-class and best-in-class small molecule therapeutics that will significantly impact patient’s lives.
Company profile
Ticker
NUVL
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Nuvalent Securities Corporation ...
NUVL stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Nuvalent Announces “OnTarget 2026” Operating Plan and Key Anticipated Milestones
9 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 88.43 mm | 88.43 mm | 88.43 mm | 88.43 mm | 88.43 mm | 88.43 mm |
Cash burn (monthly) | (no burn) | (no burn) | 12.93 mm | 11.03 mm | 7.66 mm | 7.28 mm |
Cash used (since last report) | n/a | n/a | 95.29 mm | 81.30 mm | 56.47 mm | 53.63 mm |
Cash remaining | n/a | n/a | -6.86 mm | 7.13 mm | 31.97 mm | 34.80 mm |
Runway (months of cash) | n/a | n/a | -0.5 | 0.6 | 4.2 | 4.8 |
Institutional ownership, Q4 2023
57.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 17 |
Opened positions | 4 |
Closed positions | 105 |
Increased positions | 9 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 4.42 bn |
Total shares | 34.25 mm |
Total puts | 1.00 k |
Total calls | 700.00 |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
Flynn James E | 25.47 mm | $0.00 |
Paradigm Biocapital Advisors | 3.38 mm | $172.43 mm |
Perceptive Advisors | 2.92 mm | $210.27 mm |
Bain Capital Life Sciences Fund II | 2.40 mm | $122.50 mm |
Mirae Asset Global Investments | 17.80 k | $1.31 bn |
DekaBank Deutsche Girozentrale | 17.00 k | $1.28 mm |
Ellsworth Advisors | 11.18 k | $822.44 mm |
Legato Capital Management | 7.88 k | $580.11 mm |
Arizona State Retirement System | 7.16 k | $527.20 mm |
China Universal Asset Management | 6.62 k | $487.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 May 24 | Matthew Shair | Class A Common Stock | Sell | Dispose S | No | Yes | 70.27 | 7,900 | 555.13 k | 1,462,198 |
6 May 24 | Matthew Shair | Class A Common Stock | Sell | Dispose S | No | Yes | 69.27 | 29,600 | 2.05 mm | 1,470,098 |
2 May 24 | Deborah Ann Miller | Class A Common Stock | Sell | Dispose S | No | Yes | 73.13 | 138 | 10.09 k | 33,300 |
2 May 24 | Deborah Ann Miller | Class A Common Stock | Sell | Dispose S | No | Yes | 72.58 | 1,296 | 94.06 k | 33,438 |
2 May 24 | Deborah Ann Miller | Class A Common Stock | Sell | Dispose S | No | Yes | 71.55 | 1,566 | 112.05 k | 34,734 |
2 May 24 | Deborah Ann Miller | Class A Common Stock | Option exercise | Acquire M | No | Yes | 6.89 | 3,000 | 20.67 k | 36,300 |
2 May 24 | Deborah Ann Miller | Stock Option Class A Common Stock | Option exercise | Dispose M | No | Yes | 6.89 | 3,000 | 20.67 k | 185,608 |
29 Apr 24 | Matthew Shair | Class A Common Stock | Sell | Dispose S | Yes | Yes | 68.57 | 85 | 5.83 k | 236,522 |
29 Apr 24 | Matthew Shair | Class A Common Stock | Sell | Dispose S | Yes | Yes | 67.81 | 1,082 | 73.37 k | 236,607 |
29 Apr 24 | Matthew Shair | Class A Common Stock | Sell | Dispose S | Yes | Yes | 67.01 | 833 | 55.82 k | 237,689 |
News
Nuvalent Q1 2024 GAAP EPS $(0.69) Misses $(0.68) Estimate
9 May 24
Jefferies Initiates Coverage On Nuvalent with Buy Rating, Announces Price Target of $97
17 Apr 24
Nuvalent Presents New Preclinical Data For HER2-Selective Inhibitor, NVL-330, And ROS1-Selective Inhibitor, Zidesamtinib, At AACR Annual Meeting 2024
8 Apr 24
Leerink Partners Upgrades Nuvalent to Outperform, Raises Price Target to $110
1 Apr 24
JP Morgan Maintains Overweight on Nuvalent, Raises Price Target to $98
6 Mar 24
Press releases
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
9 May 24
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
8 Apr 24
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
5 Mar 24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
27 Feb 24